Henry Schein

Henry Schein, Inc. engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution, and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, laboratory, small and large equipment repair services, branded and generic pharmaceuticals, vaccines, surgicals, diagnostic tests, infection-control products and vitamins. The Technology & Value-Added Services segment offers financial on a non-recourse basis, network and hardware services. The company was founded by Henry Schein and Esther Schein in 1932 and is headquartered in Melville, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Henry Schein reports solid Q4 performance and anticipates growth

Henry Schein's Q4 performance showcased growth amidst challenges, with a strategic focus on core margin expansion and strong performance in dental specialties. While facing challenges from declining PPE sales and supply chain issues, the company sees opportunities in stable dental markets and continued growth in operating income. Overall, the company remains optimistic about its outlook for 2023.

Henry Schein reports strong Q1 earnings, eyes growth through acquisitions

Henry Schein's Q1 2023 earnings call highlighted strong financial performance across its dental, medical, and Technology and Value-Added Services businesses. While facing challenges from declining PPE and COVID-19 test kit sales, the company remains optimistic about growth opportunities through acquisitions and stable business segments.

Henry Schein reports solid Q2 results, eyes growth opportunities

Henry Schein's Q2 performance was driven by strong dental sales, while facing challenges from declining PPE and COVID test kit sales. The company is focused on strategic acquisitions and expanding product offerings, with opportunities in technology and specialty products driving growth.

Henry Schein navigates post-cyber incident challenges, focuses on recovery

Henry Schein faced challenges from a cybersecurity incident impacting operations but showcased resilience and recovery efforts across its business segments.
Strategic initiatives focused on customer retention, operational efficiency, and cybersecurity response highlight the company's commitment to long-term growth and stability.
Despite challenges in specific segments and cybersecurity spending variables, Henry Schein's focus on recovery, cost-cutting, and customer trust positions it for future opportunities.
The company's emphasis on digital channels, stable medical demand, and strategic cost-cutting measures underscores its adaptability and strategic vision for sustained growth.

Henry Schein reports resilient Q4 performance and outlines 2024 guidance

Henry Schein's Q4 2023 performance reflects resilience amidst challenges, with a strategic focus on technology, global sales, and recovery post-cyber incident. The company's 2024 outlook includes managing residual cyber impacts and pursuing growth opportunities.

Henry Schein reports solid Q1 earnings, eyes market share expansion

Henry Schein's Q1 performance reflects resilience and growth across key segments, with a focus on market share expansion and profitability. While facing challenges in dental consumables and pricing stability, the company is leveraging opportunities in product portfolio expansion and market positioning. Strategic acquisitions and recovery efforts post-cyber incident are driving competitive strength and customer loyalty.

Henry Schein reports mixed Q2 performance, focuses on cost savings

Henry Schein navigated challenges from a cyber incident, with mixed performance across segments in Q2 2024.
Strong sales growth in dental specialties, focus on cost savings, and resilience in technology services were highlights.
The company's strategic initiatives, financial guidance update, and confidence in future prospects were key takeaways from the call.

Henry Schein excels in Q3 with strategic growth initiatives

Henry Schein's Q3 performance reflects strong market positioning and strategic execution, driving growth across key business segments.
While facing challenges such as LCI sales decline, the company's focus on operational efficiency and cost management remains a priority.
With increased sales guidance, ongoing restructuring initiatives, and strategic capital allocation plans, Henry Schein is poised for continued success and expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Henry Schein, Inc. engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, laboratory, small and large equipment repair services, branded and generic pharmaceuticals, vaccines, surgical, diagnostic tests, infection-control products, and vitamins. The Technology and Value-Added Services segment offers financial on a non-recourse basis, network, and hardware services. The company was founded by Henry Schein and Esther Schein in 1932 and is headquartered in Melville, NY.

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC) today announced its continued support of TeamSmile, a non-profit organization that provides children in need a life-changing dental experience through the power of sports. For this year's program, Henry Schein Dental, the dental business of Henry Schein, donated $30,000 in cash, nearly $40,000 in dental supplies and personal protective equipment, as well as transportation of all materials to and from 18 program sites. In additio

Henry Schein Announces Support for 2021 TeamSmile Program

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein appoints Scott Serota to Board of Directors.

Henry Schein Appoints Scott Serota to Board of Directors

Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock?

Henry Schein (HSIC) Down 10.9% Since Last Earnings Report: Can It Rebound?

The Studio Pro 4.0 launched by Henry Schein's (HSIC) orthodontics business will enable Reveal Clear Aligners providers to personalize treatment plans with greater ease and control.

Henry Schein (HSIC) Introduces Treatment Planning Software

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein Orthodontics, the orthodontics business of Henry Schein, Inc. (Nasdaq:HSIC), today announced the launch of Studio Pro™ 4.0, a new web-based treatment planning software for Reveal® Clear Aligners (Reveal). Linked to the DDX® Case Management Portal – a remote server where images are submitted and cases can be managed – Studio Pro 4.0 offers Reveal providers virtual setup tools to visualize, customize, and communicate treatment plans designed to achiev

Henry Schein Orthodontics Launches Studio Pro 4.0, Treatment Planning Software for Reveal Clear Aligners

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein Announces Lineup of New Products and Solutions at the Greater New York Dental Meeting

Henry Schein Announces Lineup of New Products and Solutions at the Greater New York Dental Meeting

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein announces participation in virtual investor conferences in December.

Henry Schein Announces Participation in Virtual Conferences in December

MELVILLE, N.Y.--(BUSINESS WIRE)--The Henry Schein Cares Foundation, in partnership with the UPS Foundation, today announced the third phase of the “Wearing is Caring” public health campaign, focused on promoting health equity to advance education about, and access to, the COVID-19 vaccines. The campaign was first launched in October 2020 with a primary focus on promoting access to health care among underserved communities, and to encourage mask-wearing as an effective measure to help reduce the

Henry Schein Cares Foundation Launches Third Phase of ‘Wearing Is Caring' Campaign

PHOENIX, Nov. 4, 2021 /PRNewswire/ -- Zimbis, a division of CUBEX LLC and provider of medication and supply management technology, announced today the launch of a partnership with Southern Anesthesia & Surgical, Inc. (SAS), a leading U.S. distributor of anesthesia and surgical supplies to oral surgeons, dental anesthesiologists, and periodontists. The partnership with SAS supports Zimbis' mission to provide clients with solutions and workflows that address their specific medication and supply requirements.

Zimbis Announces New Partnership and Launch of Order Integration with Southern Anesthesia & Surgical, Inc.

Henry Schein, Inc. (HSIC) CEO Stanley Bergman on Q3 2021 Results - Earnings Call Transcript

Strengthening demand in the global dental and medical markets drove Henry Schein's (HSIC) revenues in the third quarter.

Henry Schein (HSIC) Q3 Earnings Top Estimates, 2021 EPS View Up

Henry Schein (HSIC) delivered earnings and revenue surprises of 17.02% and 8.04%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Henry Schein (HSIC) Q3 Earnings and Revenues Top Estimates

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported record third-quarter financial results from continuing operations. Results from continuing operations exclude contributions from Henry Schein's former Animal Health business, which was spun off in February 2019 to form a new publicly traded company, Covetrus (Nasdaq: CVET). Total net sales for the quarter ended

Henry Schein Reports Record Third-Quarter 2021 Financial Results From Continuing Operations

IDEXX Laboratories

Omnicell

STERIS

With the pandemic raging on, testing, vaccine and therapeutic makers are witnessing huge market adoption of their COVID-related support products in Q3.

Medical Products Stock Earnings on Nov 2: IDXX, STE & More

Henry Schein (HSIC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Henry Schein (HSIC) This Earnings Season?

Henry Schein (HSIC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why the Earnings Surprise Streak Could Continue for Henry Schein (HSIC)

Abbott Labs

Boston Scientific

Canopy Growth

Quest Diagnostics

Insulet

Amid concerns surrounding growing COVID-19 cases affecting the medical products companies' legacy business, we are optimistic about IDXX, HSIC, CGC and PODD's results this time around.

4 Medical Products Stocks Poised to Beat This Earnings Season

Strengthening demand in the global dental and medical markets along with the recent investments are likely to have contributed to Henry Schein's (HSIC) Q3 performance.

What's in Store for Henry Schein (HSIC) in Q3 Earnings?

Henry Schein (HSIC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Henry Schein (HSIC) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein commits to set a science-based target to guide pathway for achieving net-zero emissions by 2050.

Henry Schein Joins the Business Ambition For 1.5⁰C Initiative

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC) today announced its support for two Mission of Mercy events scheduled through 2021, part of the Company's three-year commitment to America's Dentists Care Foundation (ADCF). Henry Schein's support includes donations up to $600,000 in health care products to assist in the delivery of free oral care to underserved and underrepresented communities. The Mission of Mercy (MOM) events will take place in Pittsburgh, PA (10/22-10/23) an

Henry Schein Announces Support for Mission of Mercy Events

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein to present at Credit Suisse virtual health care conference on November 9, 2021.

Henry Schein to Present at Credit Suisse Virtual Healthcare Conference

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein to webcast third quarter 2021 conference call on November 2, 2021.

Henry Schein to Webcast Third Quarter 2021 Conference Call on Tuesday, November 2, 2021 at 10:00 a.m. ET

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein CEO Stanley Bergman issues statement supporting primary-care physicians access to COVID-19 vaccines.

Henry Schein CEO Stanley M. Bergman Issues Statement Supporting Primary-Care Physician Access to COVID-19 Vaccines

This firm overcame a decline in dental services and supply chain challenges to take market share in 2020. Henry Schein's high-touch business adds considerable value to smaller dental and medical operations that have limited administrative staff and inventory storage.

News for Henry Schein Stock (HSIC)